Get the Stockscreener App
8.93
1.54%
-0.14
After Hours:
9.00
0.07
+0.78%
Aurinia Pharmaceuticals Inc stock is traded at $8.93, with a volume of 1.23M.
It is down -1.54% in the last 24 hours and up +11.21% over the past month.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
See More
Previous Close:
$9.07
Open:
$9.08
24h Volume:
1.23M
Relative Volume:
0.85
Market Cap:
$1.21B
Revenue:
$175.51M
Net Income/Loss:
$-78.02M
P/E Ratio:
-16.85
EPS:
-0.53
Net Cash Flow:
$-34.18M
1W Performance:
+3.48%
1M Performance:
+11.21%
6M Performance:
+11.62%
1Y Performance:
+59.46%
1-Day Range:
$8.91
$9.12
1-Week Range:
$8.55
$9.36
52-Week Range:
$5.195
$10.67
Aurinia Pharmaceuticals Inc Stock (AUPH) Company Profile
Name
Aurinia Pharmaceuticals Inc
Sector
Industry
Phone
250-744-2487
Address
#140, 14315 - 118 AVENUE, EDMONTON, BC
Compare AUPH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AUPH
Aurinia Pharmaceuticals Inc
|
8.93 | 1.23B | 175.51M | -78.02M | -34.18M | -0.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Aurinia Pharmaceuticals Inc Stock (AUPH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-04-22 | Downgrade | Oppenheimer | Outperform → Perform |
| May-05-22 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-10-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-28-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Jan-25-21 | Reiterated | H.C. Wainwright | Buy |
| Nov-03-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| May-05-20 | Initiated | Cowen | Outperform |
| Jan-10-20 | Initiated | Jefferies | Buy |
| Dec-16-19 | Reiterated | H.C. Wainwright | Buy |
| Mar-16-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Feb-08-18 | Initiated | RBC Capital Mkts | Outperform |
| Oct-30-17 | Reiterated | H.C. Wainwright | Buy |
| May-18-17 | Reiterated | H.C. Wainwright | Buy |
| Apr-11-17 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-22-17 | Reiterated | FBR & Co. | Outperform |
| Dec-30-16 | Reiterated | H.C. Wainwright | Buy |
| Aug-17-16 | Reiterated | H.C. Wainwright | Buy |
| Jun-30-16 | Initiated | H.C. Wainwright | Buy |
| May-08-15 | Initiated | MLV & Co | Buy |
View All
Aurinia Pharmaceuticals Inc Stock (AUPH) Latest News
Aurinia Pharmaceuticals Inc. Stock Analysis and ForecastFastest-growing stock picks - PrintWeekIndia
What analysts say about Aurinia Pharmaceuticals Inc. stockRapid growth opportunities - Autocar Professional
Is Aurinia Pharmaceuticals Inc. a good long term investmentTremendous financial leverage - Autocar Professional
Will Aurinia Pharmaceuticals Inc. stock split in the near futureHigh-octane financial growth - jammulinksnews.com
What drives Aurinia Pharmaceuticals Inc. stock priceUnmatched profit growth - Autocar Professional
When is the best time to buy Aurinia Pharmaceuticals Inc. stockSuperior profit margins - jammulinksnews.com
Aurinia Pharmaceuticals to Release Second Quarter 2025 Financial and Operational Results on July 31, 2025 - BioSpace
Aurinia Pharmaceuticals to Announce Q2 2025 Financial Results - TipRanks
Aurinia Pharmaceuticals: LUPKYNIS Growth and AUR200 Pipeline Fuel Long-Term Value - AInvest
ISS Recommends That Aurinia Shareholders Vote "FOR" All Proposals at 2025 Annual General Meeting - Yahoo.co
(AUPH) Technical Data - news.stocktradersdaily.com
Aurinia Pharmaceuticals (NASDAQ:AUPH) Delivers Shareholders Favorable 52% Return Over 1 Year, Surging 5.5% in the Last Week Alone - 富途牛牛
Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics - Yahoo
What makes Aurinia Pharmaceuticals Inc. stock price move sharplyDaily Breakout Picks - Newser
How Aurinia Pharmaceuticals Inc. stock performs during market volatilityFree Stock Investment Discussion Area - Newser
Why Aurinia Pharmaceuticals Inc. stock attracts strong analyst attentionReal Trader Insights - Newser
How did AUPH's Q3 2024 earnings surprise impact short-term traders? - AInvest
Trading (AUPH) With Integrated Risk Controls - news.stocktradersdaily.com
Wheat from chaff in BAFF: APRIL’s advent for Aurinia? - BioWorld MedTech
The Play On Aurinia Pharmaceuticals: Rising Cash Flow Provides Opportunity (NASDAQ:AUPH) - Seeking Alpha
Retail Bulls Charge Into Aurinia Pharmaceuticals Ahead Of Autoimmune Trial Results - MSN
Implied Volatility Surging for Aurinia Pharmaceuticals Stock Options - Nasdaq
Implied Volatility Surging For Aurinia Pharmaceuticals Stock Options - Barchart.com
Leerink Partners Keeps Their Buy Rating on Aurinia Pharmaceuticals (AUPH) - The Globe and Mail
Aurinia’s aritinercept shows promising results in phase 1 study - Investing.com
Aurinia Pharmaceuticals Inc Stock (AUPH) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.97%
0.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):